Keywords: update, alizyme, takeda, million, obesity, drug, development

UPDATE: Alizyme and Takeda in $42 million obesity drug development deal

Article | 18 August 2003

Print This

The UK's Alizyme has granted Japanese licensing and development rights for its promising obesity product candidate ATL-962 to Japan's Takeda ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in